Developmental Programs

Cellectar Biosciences is advancing a portfolio of internally developed radiotherapeutic programs built on its proprietary Phospholipid Ether (PLE) delivery platform. This platform selectively delivers therapeutic isotopes directly to cancer cells while minimizing exposure to normal tissue.

CLR 121125 (Auger Program)

CLR 121125 is an Auger-emitting radioconjugate that incorporates Iodine-125 to achieve intracellular delivery and DNA-level damage in tumor cells. Preclinical studies have shown activity in multiple tumor models and no evidence of end-organ toxicity. This program extends the reach of Cellectar’s platform into additional solid tumor indications.

CLR 121225 (Alpha Program)

CLR 121225 is an alpha-emitting radioconjugate that utilizes Actinium-225 as its therapeutic isotope. The program is designed to deliver highly potent, short-range alpha radiation directly to tumor cells, limiting off-target effects. Preclinical data demonstrate strong anti-tumor activity, favorable biodistribution, and high tumor uptake in solid tumor models.

Early Discovery Programs

Cellectar continues to evaluate new isotopes and payload combinations to expand the therapeutic potential of its PLE platform across both hematologic and solid tumors.